Genmab A (GMAB) Depreciation & Amortization (CF) (2024 - 2026)

Genmab A's Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 33.33% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.0 million (up 12.68% YoY) and the FY2025 annual result came in at $55.0 million, up 12.24% from the prior year.
• Depreciation & Amortization (CF) was $16.0 million for Q1 2026 at Genmab A, down from $39.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $39.0 million in Q3 2025 and bottomed at $11.0 million in Q1 2024.
• A 3-year average of $23.1 million and a median of $23.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) gained 8.33% — and 2026, when it jumped 33.33%.
• Genmab A's Depreciation & Amortization (CF) stood at $36.0 million in 2024, then increased by 8.33% to $39.0 million in 2025, then plunged by 58.97% to $16.0 million in 2026.
• Business Quant data shows GMAB's Depreciation & Amortization (CF) at $16.0 million in Q1 2026, $39.0 million in Q3 2025, and $25.0 million in Q2 2025.